Slide 1: Exchange filing cover letter
14th May, 2021 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip
Slide 2: Investor Presentation Q4FY21
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q4FY21 14-5-2021
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: We continue to remain at the forefront in the fight against COVID-19
We continue to remain at the forefront in the fight against COVID-19 CLICK TOand EDIT delivering MASTER TITLEon our promise of ‘Caring for life’ STYLE Ramping up capacities to maintain supply ❖ Remdesivir monthly supplies ❖ Ensuring availability of being ramped up to ~5x of ICMR1 recommended supplie
Slide 5: In FY21, we delivered strong performance across our focus markets
In FY21, we delivered strong performance across our focus markets CLICKand expanded TO EDIT EBITDA MASTER TITLE STYLE margins by 350bps+ EBITDA Overall Cipla Revenue 12% EBITDA 33% 22.5% 361 (YoY Growth) (YoY Growth) Margin (bps YoY) One Prescription Trade Generics Consumer Health One India India 15
Slide 6: Continued focus on maintaining a strong balance sheet
Continued focus on maintaining a strong balance sheet health and CLICK TO robust free TITLE EDIT MASTER cashSTYLE flow generation Net Debt (INR Cr) Net Debt / Equity Cash Balances1 (INR Cr) 0.05 807 Net cash Net cash 3,676 positive positive position position 2,009 (1,921) (0.10) Mar'20 Mar'21 Mar'20
Slide 7: Q4 performance demonstrates sustained performance and operational resiliency
Q4 performance demonstrates sustained performance and operational resiliency CLICK TO EDIT MASTER TITLE STYLE Overall Revenue One India Prescription Trade Generics Consumer Health Overall revenue 4% 6% Strong contribution from flagship Successful product (Q4 YoY Growth) (Q4 YoY Growth) products tran
Slide 8: Financial Performance – Q4FY21
Financial Performance – Q4FY21 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 4,606 Cr 5% YoY EBITDA INR 796 Cr │ 17.3% 22% YoY Q4 FY21 (Consolidated) Revenue1 Break-up Actuals Others, vs Q4 FY 20 API, 5% (Rs Cr) 1% Europe, 5% Total Revenue from 4,606 5% Operations Emerging Mkts, 9% India, 39% EBITDA
Slide 9: Financial Performance – FY21
Financial Performance – FY21 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 19,160 Cr 12% YoY EBITDA2 INR 4,303 Cr │ 22.5% 33% YoY FY21 (Consolidated) Revenue1 Break-up Actuals Others, vs FY 20 API, 4% (Rs Cr) 1% Europe, 5% Total Revenue from 19,160 12% Operations Emerging Mkts, 10% India, 40% 2 EBIT
Slide 10: One India: Consistent execution driving growth across businesses
One India (Rx + Gx+ CHL1): Consistent execution driving growth across CLICK TO EDITbusinesses MASTER TITLEinSTYLE India Key Business Highlights One India Prescription business ❖ Sequential normalization in-line with expectations Rs. Cr Q4 Y-o-Y ❖ Significantly expanding covid portfolio with partners
Slide 11: Global consumer health franchise
Global consumer health franchise CLICK TO EDIT MASTER TITLE STYLE 6%+ contribution to overall revenues in FY21; momentum to achieve long term aspirations Anchor consumer brands in India1 Anchor consumer brands in South Africa 139% 37% 37% 11% 48% (FY21 YoY growth (FY21 YoY growth (FY21 YoY growth) (
Slide 12: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE Key Business Highlights $ Mn South Africa Q4 Y-o-Y ❖ Solid momentum in private business; tender business in-line with expectations 40 33 ❖ ARV and oncology segments gain market share, maintain ranks and
Slide 13: North America: Continued traction in respiratory and complex generics portfolio
North America: Continued traction in respiratory and complex generics CLICK TO portfolio EDIT MASTER TITLE STYLE Key Business Highlights North America US Generics ramp-up continues ❖ Continued market share expansion in overall Albuterol market and $ Mn growth in institutional business Q4 Y-o-Y ❖ New
Slide 14: ANDA Portfolio & Pipeline (As on 31st March 2021)
ANDA1 Portfolio & Pipeline (As on 31st March 2021) CLICK TO EDIT MASTER TITLE STYLE Total ANDAs 165 19 64 248 20 56 9 4 21 80 4 13 35 10 5 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR approved
Slide 15: Emerging Markets, Europe and API
Emerging Markets, Europe and API CLICK TO EDIT MASTER TITLE STYLE Emerging Markets Europe API FY21 Y-o-Y: 21% FY21 Y-o-Y: 17% FY21 Y-o-Y: 2% $ Mn Q4 Y-o-Y $ Mn Q4 Y-o-Y $ Mn Q4 Y-o-Y 57 4% 59 32 7% 34 34 -10% 31 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Key Business Highlights Key Business Highlight
Slide 16: Our FY22 priorities include
Our FY22 priorities include CLICK TO EDIT MASTER TITLE STYLE Ramping up Covid portfolio supply to increase availability and maximize patients reach Maintain market beating growth in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise Expandin
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com